Paradise in Limbo: Hawaii’s Cannabis Journey and the Road That Keeps Closing

May 1, 2026
By RN Collins

26 years ago, Hawaii made history. In 2000, Governor Ben Cayetano signed Act 228 into law. The move made Hawaii the first state in the nation to legalize medical cannabis through its legislature — by a vote of elected representatives — rather than a ballot initiative, where voters decide a policy question directly.

The distinction mattered. While California, Oregon, and Washington had relied on voter initiatives to bypass resistant lawmakers, Hawaii’s legislature voluntarily acknowledged that cannabis had legitimate medical uses. It was a bold act of political will in an era when federal prohibition remained absolute, and the Drug Enforcement Administration was still raiding state-legal patients.

The Current State of Hawaii’s Cannabis Market

That legislative courage has not aged into legislative momentum. As of February 2026, Hawaii remains one of the few states with both a working medical cannabis program and zero pathway to adult-use legalization — no legal framework for selling cannabis to all adults rather than only registered medical patients.

The most recent attempt — House Bill 1624 — would have placed a constitutional amendment on the November 2026 ballot. It was declared effectively dead on February 8, 2026. House Speaker Nadine Nakamura told the Honolulu Star-Advertiser that an informal head count of House members found insufficient support. The pattern is now familiar. Hawaii’s cannabis story is one of repeated firsts followed by prolonged standstill, a state always at the threshold of change without crossing it.

Hawaii’s cannabis policy arrived here through a specific sequence: Act 228’s cautious optimism, the dispensary system’s troubled rollout, the program’s peak and decline, and the legislative gridlock that has blocked adult-use legalization despite strong economic evidence in its favor.

The Foundation: Act 228 and the 15-Year Wait

Act 228 was both pioneering and deliberately constrained. The law amended Chapter 329 of the Hawaii Revised Statutes (HRS) to create a medical use exemption for qualifying patients with serious conditions. Patients who got certification from a physician could register with the state and possess limited amounts of cannabis without criminal prosecution. The law also protected caregivers and certifying physicians from legal liability.

What Act 228 didn’t do was create any way for patients to legally obtain cannabis. There were no dispensaries — no licensed storefronts where patients could walk in and buy cannabis — no licensed growers, no retail system of any kind. Patients were expected to grow their own medicine or designate a caregiver to grow it for them. This assumed horticultural knowledge, physical ability, appropriate housing, and a willingness to cultivate a federally prohibited substance at home. For patients with severe medical conditions — many of whom were elderly, disabled, or living in rental housing where growing was impractical — the promise of legal medical cannabis was largely theoretical.

This gap between authorization and access persisted for 15 years. During that period, Act 178 in 2013 made small adjustments. It expanded the definition of “adequate supply” — the legal limit on how much cannabis a patient could possess — to seven plants regardless of maturity, increased the allowed quantity of usable cannabis to four ounces, and raised registration fees from $25 to $35. These were administrative tweaks to a program whose core problem — the absence of a legal supply chain — remained unsolved.

It wasn’t until 2015 that the legislature passed Act 241, formally creating the Medical Cannabis Dispensary Program and authorizing the Department of Health to license commercial dispensaries. The law created a tightly controlled market: eight dispensary licenses, each permitting up to two production centers and up to two retail locations. Licensing began in January 2016; first dispensaries opened in 2016, with additional retail locations opening through 2017.

By any fair measure, the 15-year gap between patient authorization and dispensary access failed the people it was supposed to serve. Patients who qualified for legal medical cannabis spent a decade and a half with no legal way to buy it. Their choices were to grow their own, obtain cannabis from the illicit market, or go without.

Hawaii’s Medical Cannabis Program Growth, Plateau, and Decline

Once dispensaries opened, the medical program grew steadily. Patient enrollment climbed as access improved. Legislative findings in HB 302 documented the peak: 35,444 registered patients in August 2021, roughly 2.5% of the state’s 1.4 million residents. That number reflected both genuine medical need and a practical reality: if you wanted to buy cannabis legally in Hawaii, getting a medical card was the only way.

The peak was short-lived. By June 2025, DOH data showed registered patients had fallen to 29,399 — a decline of approximately 17% over four years. Testimony in support of HB 302 in 2025 pointed to several reasons for the drop. Outdated rules required in-person physician evaluations, creating barriers for patients on the neighbor islands other than Oahu, where certifying doctors were scarce. Processing delays meant patients often waited days to receive their 329 cards, the state-issued identification required for dispensary purchases.

High dispensary prices, driven partly by limited competition among just eight licensees, pushed cost-sensitive patients toward the illicit market. The growing category of hemp-derived THC products also drew patients away. Delta-8, delta-10, and THCA are compounds that produce effects similar to conventional THC but are derived from hemp rather than marijuana. They exploited a gap in federal law that allowed them to be sold without the restrictions applied to licensed cannabis, creating a parallel market operating in plain sight.

The 2025 legislative session addressed several of these barriers. HB 302 authorized telehealth certifications, eliminating the in-person requirement that had been especially burdensome on Maui, the Big Island, and Kauai. It also expanded qualifying conditions to any provider-approved diagnosis. SB 1429 expanded caregiver growing rights, allowing a single caregiver to grow for up to five patients rather than the previous limit of one. HB 132 streamlined the expungement process — the legal procedure for erasing arrest records — for cannabis-related offenses. It built on Act 62, the 2024 pilot project that identified 2,268 Hawaii County arrest records potentially eligible for expungement under statute 712-1249 — the law criminalizing possession of marijuana and Schedule V substances. The labor-intensive manual review process had completed only 81 expungements by December 2024, with hundreds more pending or under review.

These reforms were meaningful but incremental. They improved access within the existing medical framework without addressing the core market constraints — eight licenses, 25 retail locations, no new entrants — that define the market patients are stuck with.

The Economic Case That Cannot Close the Political Deal

The economic argument for adult-use legalization in Hawaii is, by the numbers, overwhelming. An independent analysis commissioned by the DOH’s Office of Medical Cannabis Control and Regulation — prepared by Cannabis Public Policy Consulting (CPPC), published December 19, 2025 — is the most thorough assessment of Hawaii’s cannabis market to date. Hawaii’s regulated medical cannabis system generates about $5.3 million in monthly sales, roughly $64 million a year. When all sources are counted — illicit market purchases, hemp-derived products, and home growing — total cannabis spending in the state runs between $17 and $32 million per month. The legal system captures only a fraction of actual demand.

Under adult-use legalization, the CPPC report projects total market revenue could reach $59 to $95 million monthly by year five, with tourists adding at least $11.5 million per month on top of that. Meeting that demand would require roughly 65 retail locations statewide in the first year — more than double the current 25.

The report also addressed the political objection that has most consistently blocked legalization: the claim that legal cannabis would deter tourists, particularly visitors from Japan. The CPPC survey data undercuts that argument directly. Researchers found no significant link between cannabis legalization and tourism decline in Guam, a U.S. Pacific territory that legalized adult-use cannabis in April 2019. 57.5 percent of surveyed Japanese visitors reported that legalization would have no influence on their travel decisions.

The projections are conservative by design; the report uses a maximum 15% tax rate and doesn’t estimate tax revenue directly. The adult-use market could multiply Hawaii’s current $64 million in annual regulated sales by ten or more within five years.

The Legislative Graveyard of Cannabis in Hawaii

None of this has been enough to move the Hawaii House of Representatives.

The 2026 legislative session saw multiple legalization proposals. HB 1624 and SB 2420 proposed a constitutional amendment for the November 2026 ballot.

HB 1246 and its companion bills carried over from 2025 with a different approach: passing legalization as regular statute rather than amending the constitution. The bill proposed a new Hawaii Cannabis and Hemp Office, a 14% adult-use tax rate, and a 4% medical tax. It also included programs to direct legalization’s economic benefits toward communities hit hardest by cannabis prohibition, and a system for awarding licenses by random lottery rather than competitive application.

Representative David Tarnas, the Big Island Democrat who chairs the House Judiciary and Hawaiian Affairs Committee, introduced HB 1625 as a new strategy. The bill would create a regulatory framework that only takes effect if the federal government reschedules cannabis or deschedules it entirely. The approach was designed to reassure legislators uncomfortable with acting ahead of federal law.

All House-originated bills are now off the table. Speaker Nakamura confirmed on February 8 that neither HB 1624 nor HB 1625 had enough support to advance. Geographic divisions persisted, with neighbor island representatives generally supportive and parts of Oahu’s delegation opposed.

The Senate pathway remains technically alive. SB 2421 — the companion to HB 1625 — survived in the upper chamber and could theoretically cross over to the House at the session’s midpoint. Tarnas has indicated he plans to hold an informational briefing to address colleagues’ concerns, describing his approach as “courteously persistent”. The dynamics that have killed every previous legalization attempt remain unchanged.

Nakamura’s explanation was revealing. Some legislators objected to using a constitutional amendment for cannabis policy, arguing the issue “doesn’t rise to the level of a constitutional amendment where we’re changing the way government operates”. Others simply reflected their constituencies’ ambivalence. The result is a legislature that understands the problem clearly enough to commission reports on it — and not clearly enough to act.

What Hawaii’s Cannabis Patients and Workers Face Now

While the legislature deliberates, the human costs of the status quo accumulate.

Hawaii maintains one of the most restrictive decriminalization frameworks in the country. The state has reduced penalties for possessing very small amounts of cannabis to civil fines rather than criminal charges, but the threshold is extraordinarily low. Anything over three grams — roughly a week’s supply for many medical conditions — carries possible jail time and a criminal record. Hundreds of people are arrested annually under these rules, creating the paradox of a state that licenses cannabis dispensaries while simultaneously jailing people for possessing slightly more than what fits in a small container.

Employment protections for medical cannabis patients do not exist in Hawaii. Unlike most states with medical cannabis programs, patients in Hawaii can be fired for testing positive for cannabis regardless of their registered status. Workers in the cannabis industry itself have no protections for off-duty use. The state has licensed these businesses and approved this product, then allows employers to fire workers for using it.

The 2024 Clean Slate Expungement Task Force, established by the legislature and issuing its report in December 2025, acknowledged the damage that cannabis enforcement has caused. The task force described expungement and sealing of court records as “a critical mechanism to give people this opportunity — the chance to move forward with hope.” The mechanism operates in a system that continues generating new records. Arrests continue, employment consequences persist, and the three-gram threshold ensures that routine cannabis possession remains a criminal matter for anyone without a medical card.

The Path Forward for Cannabis in Hawaii and Its Obstacles

Hawaii’s cannabis trajectory is not a mystery. The economic analysis exists. The tourism data is clear. Public support, while geographically uneven, trends consistently toward legalization — at a Kauai town hall, Speaker Nakamura reported that every attendee except one raised their hand in support. The medical program’s reforms in 2025 showed that the legislature can act when the political cost is low. What remains absent is the political will to take the larger step.

Several factors could shift the calculus. Federal rescheduling of cannabis from Schedule I to Schedule III would change the risk calculation for hesitant legislators. Schedule I is the federal government’s most restrictive drug category — cannabis currently shares it with heroin and LSD, classified as having no accepted medical use. Moving to Schedule III would place cannabis alongside drugs like testosterone and Tylenol with codeine, substances the government recognizes as medically useful but still regulates. President Trump’s December 2025 executive order directed the Attorney General to complete the rescheduling process as quickly as possible. The move wouldn’t legalize cannabis, but rescheduling to Schedule III would lift the Section 280E tax burden that blocks cannabis businesses from taking standard deductions. It would also ease research restrictions and signal federal tolerance of state-level markets.

The narrow Senate pathway that remains — SB 2421 crossing over to the House — gives Tarnas and legalization advocates one more chance to build a majority. Failing that, the issue returns in 2027, 2028, and every session after — as it has since the first legalization bills were introduced over a decade ago.

The state that led the nation in legislative cannabis reform in 2000 now watches as states that legalized years later have built billion-dollar markets with tax revenues that dwarf anything Hawaii’s program produces. Hawaii’s eight licensees operate twenty-five dispensaries serving a declining patient population while billions in potential economic activity remain unrealized.

Hawaii’s legislature knows the numbers. Whether it can act on them is the question every session leaves unanswered.

About the Author

RN Collins is the staff writer at Fat Nugs Magazine, as well as 1L at Northeastern University School of Law and a neuroscientist exploring how brain health and the environment intersect. Through her writing, she bridges academic research and science communication to reframe how psychoactive plants and other traditional and alternative medicines are understood. She’s building a career that connects law, technology, and creativity—and welcomes conversations and opportunities across fields that share that vision. Connect with her on LinkedIn!